Project Details
Deciphering vulnerabilities in the USP1/Fanconi anemia axis as anticancer target in AML (A13)
Subject Area
Hematology, Oncology
Term
since 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 514894665
Synthetic lethality is a phenomenon where specific genetic events offer potential as a treatment strategy. Multiple genes of the Fanconi anemia pathway have been highly ranked as synthetic lethality genes of interest. In preliminary work a novel FANC-associated protein was identified, whose deletion leads to dysfunctionality of the USP1/FANC axis, which was shown to be critical for the response of AML cells to chemotherapy. Therefore, Lena Illert and Florian Büttner propose in A13 a holistic approach toward a new personalized treatment strategy for AML by first aiming to elucidate the deubiquitylase USP1/FANC axis as an AML vulnerability and explore its role in DNA damage repair defects. Next, they will develop AI tools to identify the optimal target drug and predict the ideal matched genetic patient population for effective implementation of synthetic lethality-based treatments.
DFG Programme
CRC/Transregios
Applicant Institution
Technische Universität München (TUM)
Project Heads
Professor Florian Buettner, Ph.D.; Professorin Dr. Lena Illert